Cipla, the largest player in the domestic drug market, could play white knight for Cipla Medpro, South Africa's third-largest drugmaker and a key ally of the Indian company. Cipla is looking to acquire around 25 per cent in the manufacturing division of Cipla Medpro, where it does not hold any stake at present.
Despite their slugfest on the high street, Korean chaebols Samsung and LG have independently charted a similar strategy that will see India operations carve out a larger slice of their global turnover
With passage of the nuclear liability Bill, the heavy engineering supply chain, led by Bharat Heavy Electricals Ltd (BHEL), Larsen & Toubro (L&T) and Bharat Forge Ltd (BFL), is gearing to take up the challenge ahead.
Just four years before, Coke factories consumed over four litres of water for every litre of beverage sold. Now, it is 2.5 litres, a reduction of 34 per cent.
Telecom operators who offer BlackBerry services are also ISPs. The feasibility of this solution, says DoT, will be explored after discussions with the Intelligence Bureau as well as the ISPs.
In a twist to the tale of drug patent infringement cases in the United States, Indian drug company Lupin has sued Ranbaxy Laboratories, which is now controlled by Japanese drug major Daiichi Sankyo, in an American court.
Huawei, the other big Chinese vendor, is yet to decide on the issue.
India Inc's bear hug with Russian consumers is getting warmer. From selling marquee cars to liquor, the relationship is heading into the next league -- joint ventures in diverse areas such as petrochemicals, telecom, pharmaceuticals and nanotechnology.
Delhi International Airport Ltd, the consortium operating Delhi airport, is close to signing a mega deal with Air India, which is making the new terminal its operational hub.
South Korean giant LG Electronics is working on using technology to revamp its product line by next year, based on three key parameters.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
Surveillance equipment to be moved from 'open' to restricted list.
The attack reflects the open schism in the association, in which TTSL is a new member with other Unified Access Service Licence holders such as Loop Telecom , Etilasat DB, Uninor and STel. The older, established, operators are represented by Bharti, Vodafone Essar and Idea Cellular.
Reliance Power (R-Power), a Reliance-Anil Dhirubhai Ambani Group (ADAG) company, is close to finalising a gas-based power plant in Gujarat with a capacity of 7,000 Mw to 8,000 Mw. This would entail an investment of around Rs 30,000 crore, based on investment levels that are normally required for power projects at present.
The Centre is mulling over creation of an independent body to regulate the country's vast retail sector. The retail regulatory authority would ensure a level playing field for indigenous retail traders if the government opens the sector to more foreign participation. The Ministry of Consumer Affairs and Food has convened a meeting on July 8 in Delhi to discuss this and other proposals and chart a comprehensive plan for the sector, according to the agenda paper of the meeting.
Loop Telecom has been looking for a strategic investor for some time now and people close to the development said the telecom operator was willing to sell up to 45 per cent stake in the firm.
L&T plans to transfer the equity of L&T in their joint ventures with Mitsubishi Heavy Industries into L&T Power through a book transfer, if clauses for the re-tender remain the same, company executives told Business Standard.
Plans to set up an integrated pharma firm in a phased manner.
Mukesh Ambani's Reliance Industries Ltd may be one of the biggest producers of natural gas in the country, but its power foray is likely to be coal or renewable energy based. The company is planning to not only bid for ultra mega power projects but also go in for acquisition of the power plants, said industry sources.
US-based Abbott Laboratories has sued Sun Pharmaceutical Industries and Ranbaxy Laboratories in courts there for challenging the patents of its cholesterol-lowering drugs, Niaspan and TriCor, respectively, in separate infringement suits.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances